Literature DB >> 4365622

Inhibition of glucagon-mediated increases in hepatic cyclic adenosine 3', 5'-monophosphate by prostaglandin E1 and E2.

F R DeRubertis, T V Zenser, R T Curnow.   

Abstract

Mesh：

Substances：

Year:  1974        PMID： 4365622     DOI： 10.1210/endo-95-1-93

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


× No keyword cloud information.
  5 in total

1.  Reduced sensitivity of the hepatic adenylate cyclase-cyclic AMP system to glucagon during sustained hormonal stimulation.

Authors:  F R DeRubertis; P Craven
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

2.  The content and metabolism of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in adenocarcinoma of the human colon.

Authors:  F R DeRubertis; R Chayoth; J B Field
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

3.  Structural specificity for prostaglandin effects on hepatocyte glycogenolysis.

Authors:  E P Brass; M J Garrity
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

4.  Prostaglandin F2 alpha and the thromboxane A2 analogue ONO-11113 stimulate Ca2+ fluxes and other physiological responses in rat liver. Further evidence that prostanoids may be involved in the action of arachidonic acid and platelet-activating factor.

Authors:  J G Altin; F L Bygrave
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

5.  Effect of prostaglandins on hepatic cyclic nucleotide concentration, carbohydrate and lipid metabolism.

Authors:  R A Levine
Journal:  Yale J Biol Med       Date:  1979 Jan-Feb
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.